Johan Luthman

AI Summary

→ WHAT IT COVERS Johan Luthman, EVP of R&D at Lundbeck, details how he rebuilt the company's neuroscience pipeline from near-zero innovation spend, using a focused biology-first strategy, early proof-of-concept studies, and targeted acquisitions to generate multiple novel mechanism validations in humans over four years. → KEY INSIGHTS - **R&D Productivity Formula:** Luthman applies a framework borrowed from Eli Lilly where productivity equals (number of assets × PTRS × market value) divided by (time × money). He prioritizes increasing PTRS — probability of technical and regulatory success — above all else, treating time as the second lever and money as the least critical variable in the equation. - **Phase 1b Patient Studies as Risk Reduction:** Before entering Phase 2, Lundbeck runs Phase 1b studies in patients to confirm target occupancy and biological effect in humans. This "let the molecules speak early" approach generates proof-of-concept data that reduces late-stage failure risk and avoids the largest cost in drug development — opportunity cost from failed Phase 3 trials. - **Biology Over Disease Modeling:** Luthman instructs researchers to model biological mechanisms rather than diseases, particularly in psychiatry where animal models of conditions like depression lack validity. This reframe generates measurable biomarkers tied to genetic and mechanistic validation, enabling more rigorous go/no-go decisions before committing significant capital to clinical programs. - **Portfolio Budget Reallocation:** When Luthman joined Lundbeck, 65% of the R&D budget was allocated to lifecycle management of existing drugs, leaving only 5–7% for genuine innovation. Redirecting that spend toward early-stage external partnerships, preclinical acquisitions, and novel mechanism programs — including the Alder Biotherapeutics acquisition for monoclonal antibody capability — rebuilt the pipeline within seven years. - **Foundation Ownership as Strategic Advantage:** Lundbeck's foundation ownership structure eliminates hostile acquisition risk and enforces long-term thinking, with profits funding Danish academic research grants and the Brain Prize — neuroscience's equivalent of the Nobel. This structure allows R&D leadership to pursue multi-year rare disease and novel mechanism programs without short-term shareholder pressure disrupting pipeline strategy. → NOTABLE MOMENT Luthman recounts that both AstraZeneca and early pharma analysts dismissed multiple sclerosis as a market too small to pursue. Within five years of his departure from that program, MS had grown into a sixteen-billion-dollar market — a pattern he consciously repeated when entering migraine prevention at Lundbeck. 💼 SPONSORS None detected 🏷️ Neuroscience Drug Discovery, R&D Pipeline Strategy, Rare Disease Development, Biotech M&A, AI in Clinical Trials